How AI is Transforming Clinical Trials

#Digital_twins are emerging as a transformative tool in modernizing randomized clinical trials (#RCT). This paper by Hossein Akbarialiabad and colleagues illustrates how digital twins can enhance evidence generation: 1. Virtual patient generation: AI models combine clinical, imaging, genomic, lifestyle, and historical trial data to create synthetic patient profiles that reflect real-world diversity, moving beyond the narrow slices typically enrolled in trials. 2. Simulation of virtual cohorts: Digital twins can act as synthetic controls or virtual treatment recipients, minimizing placebo exposure, reducing sample sizes, and allowing in-silico exploration of safety and efficacy prior to involving real patients. 3. Predictive modeling and optimization: Adaptive designs, dose optimization, SHAP-based interpretability, and continuous model refinement contribute to smarter, faster, and more transparent trials. Encouragingly, real-world applications are already demonstrating significant impacts: - In cardiology, the inEurHeart RCT utilized a cardiac digital twin for ventricular tachycardia ablation, resulting in 60% shorter procedures and 15% higher acute success rates. - In diabetes, a digital-twin-powered assistant in a 12-week RCT for older adults with type 2 diabetes lowered HbA1c by 0.48%, reduced mental distress, and improved self-care adherence. - In oncology, digital twins that integrate tumor-growth models with imaging are personalizing therapy and simulating treatment responses, advancing precision oncology. - In drug development, digital twins facilitate in-silico trials and early safety assessments, accelerating discovery, reducing reliance on animal studies, and enhancing early-phase decision-making. While digital twins show real promise, their impact will depend on rigorous validation, transparent methods, strong privacy safeguards, and thoughtful regulatory pathways. They won’t replace RCTs, but can meaningfully strengthen them, making evidence generation more efficient, inclusive, and patient‑centered. Interested readers may refer to the attached paper below for more details and share your comments.

AI could make clinical trials faster, cheaper, and more inclusive, but success depends on explainability, interoperability, and trust. 1️⃣ 80% of trials face recruitment delays, and 50% of datasets contain quality issues; AI aims to fix both. 2️⃣ Machine learning improves protocol design accuracy (80% vs. 65%) and accelerates site selection and feasibility assessments. 3️⃣ AI tools boost enrollment by up to 65% and cut screening time by 78%, though real-world deployment can be costly and complex. 4️⃣ NLP and digital systems help identify underrepresented groups, supporting more diverse and inclusive recruitment. 5️⃣ AI-driven digital biomarkers enable 90% sensitivity in real-time safety monitoring, improving adverse event detection. 6️⃣ Risk-based monitoring powered by AI detects data integrity issues within 48 hours, much faster than manual reviews. 7️⃣ Predictive models achieve 85-90% accuracy in forecasting outcomes and enable adaptive, personalized trial designs. 8️⃣ High-dimensional, noisy, and heterogeneous data challenge AI systems; success requires strong data harmonization and validation. 9️⃣ Regulatory gaps, stakeholder distrust, and lack of explainability remain major barriers to clinical adoption. 🔟 Real-world trials show AI's promise, but also its high cost, customization demands, and integration hurdles. ✍🏻 David Olawade (MPH, FRSPH, FHEA), Sandra Chinaza Fidelis (RN, BNSc, MSc, MPH), Sheila Marinze, Eghosasere Egbon, Ayodele Osunmakinde, Augustus Osborne. Artificial intelligence in clinical trials: A comprehensive review of opportunities, challenges, and future directions. International Journal of Medical Informatics. 2026. DOI: 10.1016/j.ijmedinf.2025.106141

Artificial intelligence is rapidly reshaping the clinical research landscape, and this new review, “Artificial intelligence in clinical trials: A comprehensive review of opportunities, challenges, and future directions”, published in the International Journal of Medical Informatics, provides one of the most detailed analyses to date. The paper outlines how AI can improve nearly every phase of the trial lifecycle, from protocol design and patient recruitment to data monitoring and predictive outcome modelling, showing tangible performance gains such as shorter timelines, lower costs, and improved data quality. Yet, what stands out most to me is not the promise of automation but the depth of the implementation challenges. Data interoperability gaps, regulatory uncertainty, and stakeholder trust remain critical bottlenecks. Without addressing these, efficiency gains risk being offset by ethical, technical, and governance concerns. The review’s emphasis on risk-stratified implementation, explainability, and bias mitigation provides a timely reminder that AI in clinical research is not merely a technical evolution but a systemic transformation, one that demands transparency, validation, and interdisciplinary collaboration. This study serves as a valuable reference point for researchers, developers, and regulators aiming to translate AI’s potential into real clinical impact while maintaining patient safety and scientific integrity. https://lnkd.in/gUfAZeBy #ClinicalResearch #ArtificialIntelligence #DigitalHealth #ClinicalTrials #AIinHealthcare #HealthInnovation #EthicsInAI #DataQuality #PatientCentricCare #TranslationalMedicine #HealthTechnology

What happens when AI models become as trustworthy as clinical data? The answer could redefine drug development entirely: Drug development has always followed the same path: discovery, preclinical, clinical, regulatory, launch. Each phase took years, each step consumed capital. AI is now reshaping that entire cycle. Not just how drugs are discovered, but how they’re tested, approved, and commercialized. 1. Discovery: Faster Target-to-Candidate Nearly 30% of new preclinical candidates now come from AI pipelines. Platforms like Atomwise, BenevolentAI, and Insilico Medicine combine genomics and chemistry data to find targets, design molecules, and predict interactions. Discovery timelines are dropping up to 40%, costs by 30%. Partnerships such as AstraZeneca’s $555M deal with Algen Biotech show the shift from single assets to scalable discovery systems. 2. Preclinical: Reducing Animal Testing The FDA Modernization Act (2022) authorized AI toxicity and organ-on-chip models as non-animal alternatives. By 2025, pilot IND programs now accept validated AI and organ-chip data, removing months from preclinical cycles. Earlier go/no-go decisions and better human relevance are driving faster IND readiness. 3. Clinical: From Months to Weeks AI accelerates recruitment, site selection, and adaptive design. Patient matching that once took months now happens in days. Digital-twin models reduce participants while maintaining statistical power. FDA’s 2025 guidance defines how “AI model credibility” must be proven: clear context, explainability, and monitoring. Experts expect clinical programs 30–50% shorter by 2030. Could regulators ever skip Phase 1 studies if AI models predict safety and dose outcomes? Not yet, but hybrid models pairing AI evidence with smaller human trials are emerging. 4. Regulatory and Launch AI already supports dossier preparation, evidence synthesis, and risk analysis. Regulators now expect transparent validation and lifecycle monitoring for any AI used in submissions. Commercially, AI drives forecasting, access strategy, and post-market analytics. By 2030, it may function as the operating system for commercialization itself. 5. Proprietary vs Open AI Pharma is dividing. Some build closed, proprietary models for control and IP protection. Others favor open frameworks for speed and collaboration. The likely future is hybrid: closed models refined on private data, open components for discovery and interoperability. Computational evidence is becoming as strategic as clinical data. 3 Signals for Executives: • Is your team treating AI as core infrastructure, not a pilot? • Are you investing in regulatory-grade model validation and lifecycle monitoring? • Is your platform strategy built for transparency and collaboration with regulators and partners? At Kybora.com, we help leaders navigate this transformation, aligning science, capital, & execution in the AI-enabled future of biopharma.

World Economic Forum: Intelligent Clinical Trials: Using #GenAI Generative AI to Fast-Track #Therapeutic #Innovations Generative AI promises to help bring therapeutic innovation to patients more quickly – and to reduce the costs. Stakeholders throughout the life sciences field and beyond have struggled for decades to bring new therapies to patients faster and at lower cost. Inefficiencies in clinical development are the primary obstacle, and despite sustained focus and investment from the healthcare industry, the problem has only intensified. Gen AI is already being used to revolutionize drug discovery. While this is vital work, clinical development bottlenecks are the bigger impediment to therapeutic innovation. In interviews, clinical development leaders throughout the pharmaceutical industry, tech sector, NGOs and more stated their belief that Gen AI will also revolutionize clinical development. It will do this by enabling new forms of trials, such as decentralized clinical trials (DCTs), and improving existing forms through integrating new data streams, including from real-world evidence (RWE). While DCTs have shown promise in expanding trial participation, reducing patient burden and improving trial efficiency, their complexity has so far hindered widespread adoption. With smart investments and an enabling environment, Gen AI can help development teams optimize trial design, improve trial feasibility and site selection, overhaul clinical operations, automate data analysis and speed up and error-proof regulatory submissions. Beyond transforming traditional trials, Gen AI also opens the door to entirely new approaches to clinical research built on real-time RWE, adaptive designs and continuous learning. A ZS analysis found that a typical top-10 pharma company would realize cost savings of more than $1 billion over five years just from implementing AI-driven trial design and decentralized trial execution. The cost and time savings will be even higher when companies infuse AI across the entire clinical development process. There are obstacles to making this a reality, however: a fragmented data ecosystem; insufficient data standards and infrastructure; a lack of system-wide incentives for data sharing; industry inertia; a murky regulatory environment; and skill gaps. This white paper calls on policy-makers, life sciences professionals and others to unite around the cause of using the power of Gen AI to improve clinical development.

AI & Real-World Data: Transforming Clinical Trial Recruitment. Clinical trial recruitment remains one of the largest barriers to delivering new therapies to patients. AI and real-world data (RWD) are transforming this process — enabling faster identification, better matching, and more inclusive enrollment across therapeutic areas. Key AI opportunities. - AI-powered patient identification – Advanced algorithms mine EHRs, registries, and genomic/lab datasets to find eligible patients in real time, even for complex biomarker-driven protocols, while improving diversity by identifying underrepresented populations. - Patient-centric engagement – AI navigators, chatbots, and personalized outreach guide patients and caregivers from trial discovery through eligibility verification, documentation, and site connection — offering 24/7 support to reduce drop-offs. - Site enablement – Automated pre-screening, point-of-care recruitment tools, and integrated diagnostic AI (e.g., endoscopy AI for IBD) cut manual workload, lower screen failure rates, and accelerate first-patient-in timelines. - Sponsor intelligence – RWD-driven feasibility and predictive analytics optimize protocol criteria, site selection, and enrollment targets; real-time monitoring enables proactive adjustments to keep timelines on track. Therapeutic Area Specific Opportunities. * Oncology – Rapid identification of biomarker-specific candidates from pathology/genomic reports; AI prompts at point-of-care improve referrals; targeted outreach drives diversity in trial participation. * Neuroscience – Predictive AI models forecast disease progression in Alzheimer’s and other CNS disorders, reducing high screen-failure rates and ensuring timely enrollment of patients most likely to benefit. * Immunology – Embedding AI into diagnostic workflows (e.g., colonoscopy scoring in IBD) identifies candidates during standard care; lab and imaging AI tools match patients with rare biomarker requirements. * Cardiovascular – AI processes data from wearables, remote sensors, and EHRs to identify and risk-stratify patients; decentralized trial models expand reach to rural and mobility-limited populations. * Rare diseases – AI harmonizes patient registry data globally to locate small, geographically dispersed populations, matching patients to highly specialized trials in record time. Global challenges in use of AI. Variability in data digitization, interoperability, privacy laws, and regulatory acceptance requires flexible, region-specific AI strategies to remain compliant and effective. At Thermo Fisher Scientific’s PPD clinical research business, we’re delivering these innovations today. Our Patient First digital solutions and TrialMed™ platform integrate AI-enabled patient recruitment, global site networks, and home trial services to bring trials directly to patients, reduce site burden, and meet or exceed enrollment timelines — accelerating life-saving innovation delivery worldwide.

🧬 The $2.6 Billion Problem: How Virtual Patients Are Revolutionizing Drug Development Here's a sobering reality: 9 out of 10 drugs fail in clinical trials after billions in investment. Each approved drug costs $2.6 billion and takes over 10 years to develop. This isn't just expensive—it's unsustainable. But AI-powered virtual patients are changing everything. What are virtual patients? Think digital twins of human physiology—sophisticated AI simulations trained on massive datasets of patient records, biological processes, and clinical outcomes. They can predict how drugs will behave in the human body, and even in individual human bodies, before a single person takes them. The game-changing impact:  🎯 Early failure detection - Identify toxicity and efficacy issues before expensive human trials  ⚡ Precision dosing - Test thousands of dosing regimens across diverse populations virtually  🔬 Biomarker discovery - Accelerate identification of which patients will benefit most  💰 Cost reduction - 30-50% savings in preclinical phases alone Beyond cost savings, this is strategic transformation: ▪️ Faster go/no-go decisions in drug discovery ▪️ Better patient stratification for trials ▪️ Reduced ethical concerns around human and animal testing ▪️ Democratized innovation for smaller biotechs The FDA approved virtual patient use in clinical trials in October 2022 and the first drugs leveraging these are making their way through the clinical trial process. Now the FDA and EMA are seeking to do more to incentivize model-informed drug development Model-Informed Drug Development (MIDD), paving regulatory pathways for widespread virtual patient data in submissions. The bottom line: We're moving from reactive risk management to proactive outcome engineering. Virtual patients aren't just accelerating drug development—they're making precision medicine accessible at scale. For patients waiting for life-saving treatments, this can't come fast enough. What's your take on AI simulation in healthcare? Are we ready for this virtual-first future? #AI #Pharma #DrugDevelopment #VirtualPatients #DigitalHealth #Innovation #PrecisionMedicine

🔬 Transforming Clinical Trials Through AI: A New Era The reality is sobering: Up to 12 years and $2.5B to bring a treatment to market. 85-90% failure rate. But innovation is accelerating. The World Economic Forum's latest research highlights five game-changing areas where Generative AI is reshaping clinical development: - Optimizing trial designs with predictive insights - Streamlining regulatory processes - Enhancing patient participation - Accelerating data analysis - Improving site selection accuracy From the report: "Roughly 60% of trial protocols require at least one amendment, nearly half of which are considered 'avoidable' - costing pharmaceutical companies $2 billion per year." The potential? Top pharmaceutical companies could save over $1B in just five years through AI innovation. Major challenges exist: data fragmentation, regulatory uncertainty, and resistance to change. Moving forward demands collaboration: • Unified data standards • Robust shared infrastructure • Clear AI guidelines • Cultural evolution This isn't just about efficiency – it's about accelerating life-saving therapies. #Healthcare #ClinicalTrials #AI #Innovation #FutureOfMedicine WEC white paper: https://lnkd.in/gSZ4hjHp Image: Fig. 1 - A use-case prioritization framework for Gen AI in clinical development. WEC white paper (ZS analysis)

📌 Artificial Intelligence in Clinical Research, Opportunities, Challenges, and the Future of AI-Driven Trials Artificial intelligence is rapidly entering the world of clinical research. From trial design to post-market surveillance, AI tools are beginning to support tasks that once required extensive manual work. A recent review in the Journal of Medical Artificial Intelligence highlights how machine learning, natural language processing and deep learning are being used across the entire clinical trial lifecycle. Several areas stand out. 1️⃣ AI can help improve trial design by analysing historical data and predicting recruitment feasibility. 2️⃣ It can support patient recruitment by scanning electronic health records and identifying eligible participants more efficiently. 3️⃣ In medical imaging, deep learning models can analyse complex scans and detect patterns linked to disease progression or treatment response. 4️⃣ AI also plays a growing role in real-world evidence. By analysing large datasets from registries, claims databases and digital health tools, AI can help generate insights into treatment effectiveness in routine clinical practice. However, the adoption of AI in clinical research also raises important questions. Data quality, model transparency and algorithmic bias remain important challenges. Regulators such as the FDA and EMA are actively developing guidance on how AI systems should be validated and monitored. The key point is simple. 🔊 AI is not replacing scientific judgement. It is becoming another tool in the evidence generation ecosystem. Used responsibly, it can help researchers analyse complex datasets, identify meaningful patterns and improve the efficiency of clinical trials. As clinical research continues to evolve, the integration of AI will likely become an increasingly important part of how evidence is generated and evaluated. 📚 Reference: Miao M, Ma P. Applications of artificial intelligence in clinical research: a narrative review of recent advances and challenges. Journal of Medical Artificial Intelligence. 2026;9:17. doi:10.21037/jmai-2025-114. 🔑 Keywords: #ArtificialIntelligence #ClinicalTrials #RealWorldEvidence #RWE #MachineLearning #DrugDevelopment #DigitalHealth ⚖️ Disclaimer: Views expressed here are my own. Helios Academy Ltd — “Where Science Meets Compassion” — is an independent educational initiative. This post does not represent the views of Astellas Pharma, my employer, and contains no confidential or company-related information.

🧠 The New Standard: AI Is Redefining Clinical Trials: How AI Is Transforming Design, Execution & Disclosure 💡 As we continue to explore how AI and agentic systems are reshaping healthcare, I found Citeline’s latest Strategic Playbook — “The New Standard: How AI Is Reshaping Trial Design, Execution, and Disclosure” particularly insightful. It reinforces a truth we’re all beginning to see: AI is no longer experimental in clinical trials — it’s operational. Rather than replacing clinicians or regulatory experts, AI is quietly augmenting them — Automating manual steps in protocol design and cohort feasibility Optimizing investigator and site selection Accelerating regulatory disclosure and transparency Delivering faster, more inclusive, and data-driven decisions Examples such as Protocol SmartDesign, Cohort SmartBuilder, Investigator SmartSelect, Ella AI Assistant, and TrialScope Disclose with AI Importer demonstrate how intelligent systems are now woven into the entire clinical trial lifecycle — from design to compliance. This is the new foundation of AI-enabled clinical operations: practical, interoperable, and outcome-driven. The organizations that adapt early — integrating AI into feasibility, compliance, and transparency workflows — will define the next decade of trial efficiency and ethical innovation. 📘 The playbook, published by Citeline, offers a valuable blueprint for building AI-ready trial ecosystems. #ClinicalTrials #AIinHealthcare #AgenticAI #AIAgents #DigitalHealth #ClinicalInnovation #LifeSciences #RegulatoryCompliance #ClinicalResearch